Eqis Capital Management, Inc. Crispr Therapeutics Ag Transaction History
Eqis Capital Management, Inc.
- $1.19 Billion
- Q1 2024
A detailed history of Eqis Capital Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 6,559 shares of CRSP stock, worth $357,859. This represents 0.04% of its overall portfolio holdings.
Number of Shares
6,559
Previous 8,447
22.35%
Holding current value
$357,859
Previous $528,000
15.34%
% of portfolio
0.04%
Previous 0.04%
Shares
13 transactions
Others Institutions Holding CRSP
# of Institutions
547Shares Held
56.2MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$445 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$428 Million0.11% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$178 Million2.23% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$172 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.7MShares$148 Million0.11% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.26B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....